%0 Journal Article
%T Syndecan-1 Levels in Females with Active Rheumatoid Arthritis.
%A Rodriguez-Jimenez NA
%A Gonzalez-Ponce F
%A Gamez-Nava JI
%A Ramirez-Villafaña M
%A Saldaña-Cruz AM
%A Ponce-Guarneros JM
%A Olivas-Flores EM
%A Macías-Islas MA
%A Valdivia-Tangarife ER
%A Jacobo-Cuevas H
%A Ramos-Estrada LG
%A Totsuka-Sutto S
%A Cardona-Muñoz EG
%A Gonzalez-Lopez L
%A On Behalf Of The Group For The Assessment Of Prognosis Biomarkers In Autoimmune Disorders 
%J J Clin Med
%V 13
%N 14
%D 2024 Jul 14
%M 39064151
%F 4.964
%R 10.3390/jcm13144110
%X Background: The relationship between serum glycoprotein syndecan-1 and disease activity in rheumatoid arthritis (RA) is still unknown. This study aimed to evaluate whether serum syndecan-1 concentrations are associated with moderate/severe disease activity. Methods: Study Design: This was a cross-sectional study. Seventy-five adult women with RA were classified into (a) moderate/severe RA based on the disease activity score, using the erythrocyte sedimentation rate (DAS28-ESR ≥ 3.2, n = 50), and (b) RA in remission (DAS28-ESR < 2.6, n = 25). Twenty-five healthy women were taken as the reference group. Syndecan-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). High values of serum syndecan-1 levels (≥24 ng/mL) were used to identify the utility values of this biomarker. Results: The patients with RA had higher levels of syndecan-1 than the controls (p < 0.001). RA patients with active disease had higher syndecan-1 levels than RA patients in remission (57.6 vs. 23.5 ng/mL, respectively; p = 0.002). High syndecan-1 concentrations demonstrated the following utility values for identifying disease activity: sensitivity, 84% (95%CI: 71-93); specificity, 52% (95%CI: 31-72); positive predictive value, 78% (95%CI: 70-84); and negative predictive value, 62% (95%CI: 44-77). Conclusions: High syndecan-1 levels have good sensitivity and positive predictive value for identifying disease activity; however, their specificity is limited. Future prospective studies are needed to assess whether syndecan-1 levels can predict treatment failure in RA.